Atlas Trials

Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies

Clinical trial NCT02238509 · UNKNOWN

Trial details

NCT number
NCT02238509
Sponsor
Consorzio Oncotech
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2014-11-01
Primary completion
2017-10-01
Enrollment
154

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.